Biotech Values

[hptaxis]

MEDIVIR SER B SEK5 (PINK:MVRBF) http://www.medivir.se/v4/en/index.cfm
Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 3 clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.

GF: http://www.google.com/finance?q=PINK:MVRBF

Financial Statement, 1 January – 31 December 2011
http://www.medivir.se/v4/en/ir_media/pressrelease.cfm
Cash flow from operating activities amounted to SEK 57.3 (-76.9) m; cash and cash equivalents and investments in securities etc. amounted to SEK 536.3 (647.2) m at the end of the period.


2010 AR
http://www.medivir.se/v4/images/pdf/2011/2010_Medivir_webb_E.pdf